S
Shiva Krupa
Researcher at Novartis
Publications - 10
Citations - 2409
Shiva Krupa is an academic researcher from Novartis. The author has contributed to research in topics: BioPAX : Biological Pathways Exchange & Neuroblastoma. The author has an hindex of 5, co-authored 8 publications receiving 2037 citations. Previous affiliations of Shiva Krupa include SRA International.
Papers
More filters
Journal ArticleDOI
PID: the Pathway Interaction Database.
Carl F. Schaefer,Kira Anthony,Shiva Krupa,Jeffrey Buchoff,Matthew Day,Timo Hannay,Kenneth H. Buetow +6 more
TL;DR: The Pathway Interaction Database (PID), a freely available collection of curated and peer-reviewed pathways composed of human molecular signaling and regulatory events and key cellular processes, serves as a research tool for the cancer research community and others interested in cellular pathways.
Journal ArticleDOI
The BioPAX community standard for pathway data sharing
Emek Demir,Emek Demir,Michael P. Cary,Suzanne M. Paley,Ken Fukuda,Christian Lemer,Imre Vastrik,Guanming Wu,Peter D'Eustachio,Carl F. Schaefer,Joanne S. Luciano,Frank Schacherer,Irma Martínez-Flores,Zhenjun Hu,Verónica Jiménez-Jacinto,Geeta Joshi-Tope,Kumaran Kandasamy,Alejandra López-Fuentes,Huaiyu Mi,Elgar Pichler,Igor Rodchenkov,Andrea Splendiani,Andrea Splendiani,Sasha Tkachev,Jeremy Zucker,Gopal R. Gopinath,Harsha Rajasimha,Harsha Rajasimha,Ranjani Ramakrishnan,Imran Shah,Mustafa H Syed,Nadia Anwar,Özgün Babur,Özgün Babur,Michael L. Blinov,Erik Brauner,Dan Corwin,Sylva L. Donaldson,Frank Gibbons,Robert N. Goldberg,Peter Hornbeck,Augustin Luna,Peter Murray-Rust,Eric K. Neumann,Oliver Reubenacker,Matthias Samwald,Matthias Samwald,Martijn P. van Iersel,Sarala M. Wimalaratne,Keith Allen,Burk Braun,Michelle Whirl-Carrillo,Kei-Hoi Cheung,Kam D. Dahlquist,Andrew Finney,Marc Gillespie,Elizabeth M. Glass,Li Gong,Robin Haw,Michael Honig,Olivier Hubaut,David W. Kane,Shiva Krupa,Martina Kutmon,Julie Leonard,Debbie Marks,David Merberg,Victoria Petri,Alexander R. Pico,Dean Ravenscroft,Liya Ren,Nigam H. Shah,Margot Sunshine,Rebecca Tang,Ryan Whaley,Stan Letovksy,Kenneth H. Buetow,Andrey Rzhetsky,Vincent Schächter,Bruno S. Sobral,Ugur Dogrusoz,Shannon K. McWeeney,Mirit I. Aladjem,Ewan Birney,Julio Collado-Vides,Susumu Goto,Michael Hucka,Nicolas Le Novère,Natalia Maltsev,Akhilesh Pandey,Paul Thomas,Edgar Wingender,Peter D. Karp,Chris Sander,Gary D. Bader +94 more
TL;DR: Thousands of interactions, organized into thousands of pathways, from many organisms are available from a growing number of databases, and this large amount of pathway data in a computable form will support visualization, analysis and biological discovery.
Journal ArticleDOI
PID: The Pathway Interaction Database
Carl F. Schaefer,Kira Anthony,Shiva Krupa,Jeffrey Buchoff,Matthew Day,Timo Hannay,Kenneth H. Buetow +6 more
TL;DR: The Pathway Interaction Database (PID), a freely available collection of curated and peer-reviewed pathways composed of human molecular signaling and regulatory events and key cellular processes, serves as a research tool for the cancer research community and others interested in cellular pathways.
Journal ArticleDOI
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Andrew C. Wood,Kateryna Krytska,Hannah T. Ryles,Nicole R. Infarinato,Renata Sano,Theodore D. Hansel,Lori S. Hart,Frederick J. King,Timothy R. Smith,Edward K. Ainscow,Kathryn B. Grandinetti,Tove Tuntland,Sunkyu Kim,Giordano Caponigro,You Qun He,Shiva Krupa,Nanxin Li,Jennifer L. Harris,Yael P. Mosse +18 more
TL;DR: This preclinical combination drug screen with in vivo validation has provided the rationale for a first-in-children trial of combination ceritinib and ribociclib in a molecularly selected pediatric population.
Journal ArticleDOI
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Lori S. Hart,JulieAnn Rader,Pichai Raman,Vandana Batra,Mike R. Russell,Matthew Tsang,Maria Gagliardi,Lucy Chen,Daniel Martinez,Yimei Li,Yimei Li,Andrew Wood,Sunkyu Kim,Sudha Parasuraman,Scott Delach,Kristina A. Cole,Kristina A. Cole,Shiva Krupa,Markus Boehm,Malte Peters,Giordano Caponigro,John M. Maris,John M. Maris +22 more
TL;DR: Combined binimetinib and ribociclib treatment shows therapeutic synergy across a broad panel of high-risk neuroblastoma preclinical models, and these data support testing this combination therapy in relapsed high- risk neuroblastomas patients, with focus on cases with hyperactivated RAS–MAPK signaling.